Table 1.

Microbiological study of therapeutic efficacy of GM237354 against oral candidiasis in ratsa

Total dose (mg/kg/day) Regimen (mg/kg)Day 4 Day 7
No. of infected animals/total (%) Log CFU/swab (mean ± SD) No. of infected animals/total (%) Log CFU/swab (mean ± SD)
None13/13 (100)4.0 ± 0.7 13/13 (100)3.9 ± 0.6
3.75 1.25 TID5/5 (100) 3.6 ± 0.9 4/5 (80) 2.7 ± 0.8
55 OD 5/5 (100) 3.7 ± 0.8 4/5 (80)2.4 ± 0.4
7.5 2.5 TID 5/5 (100)2.8 ± 0.3 3/5 (60) 2.5 ± 0.3
10 5 BID5/5 (100) 3.3 ± 0.5 3/5 (60) 2.6 ± 0.4
15 5 TID 2/5 (40) 2.7 ± 0.3 0/5 (0)<1.6∗∗
30 10 TID 0/5 (0)<1.6∗∗ 0/5 (0)<1.6∗∗
  • a Rats were orally infected three times at 24-h intervals with 3 × 108 C. albicans4711E cells/ml. GM237354 was administered subcutaneously once a day (OD), twice a day (BID), or TID for seven consecutive days (day 0 to day 6). The mean log CFU/swab just before treatment was 5.0 ± 0.7 (n = 43) . ∗, P < 0.05 ; ∗∗, P < 0.01 (versus the control treatment). The limit of detection was 40 CFU/swab.